Skip to content

CLINICAL STUDY OF AROGYAVARDHINI COMPOUND AND LIFESTYLE MODIFICATION IN MANAGEMENT OF METABOLIC SYNDROME

Double blind placebo controlled Pharmaco-clinical study of Arogyavardhini compound and lifestyle modification in management of metabolic syndrome

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/06/005833
Enrollment
60
Registered
2015-06-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients of metabolic syndrome fulfilling inclusion criteria and willing to participate in clinical trial

Interventions

Intervention1: Arogyavardhini Compound and Lifestyle modification: Arogyavardhini compound contains equal quantity of Arogyavardhini rasa and single bulb Lasuna powder while lifestyle modification inc

Sponsors

Ayush department
Lead Sponsor
Institute for post graduate teaching and research in ayurveda
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Abdominal obesity, (waist circumference >90 cm in men and >80 cm in women) Hypertriglyceridaemia (S.Triglycerides level 150-600 mg/dl); Low HDL cholesterol (S.HDL cholesterol Elevated blood pressure (Systolic blood pressure 130-160 mmHg and/or diastolic blood pressure 85-100 mmHg); Impaired fasting glucose (Fasting plasma glucose 100-200 mg/dl).

Exclusion criteria

Exclusion criteria: • Age below 20 and above 60 years • Patients suffering from type 1 Diabetes mellitus and uncontrolled diabetes mellitus & uncontrolled hypertension • Drug induced & uncontrolled dyslipidemia • Systemic illness like Tuberculosis, Carcinoma and Endocrine disorders like Cushing syndrome, Hypothyroidism • Patient having the past history of M.I. & Unstable Angina. • Patient having Clinical Features of CCF • Patient having the major renal or liver disorder

Design outcomes

Primary

MeasureTime frame
It is expected that the trial drugs will exert a significant action on metabolic syndrome.Timepoint: 8 weeks

Secondary

MeasureTime frame
By providing better effect on metabolic syndrome, drug may also reduce the risk of diabetes, CVA and IHD.Timepoint: 8 weeks

Countries

India

Contacts

Public ContactBharatkumar C Padhar

Institute for post graduate teaching and research in Ayurveda Gujarat Ayurved University Jamnagar

alankruta@yahoo.com9824171817

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026